Menu
Enrolling by invitation NCT07280221

WEgovy Real World Assessment of Weight Loss in Korea

— Observational Obesity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Semaglutide.
Who it may be relevant to
Registry conditions: Obesity. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea

Overview

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Interventions

  • Drug Semaglutide
    Semaglutide injection will be self-administered once weekly subcutaneously.

Primary outcome measures

  • Percentage change in body weight [Time frame: From baseline (week 0) to 24 weeks]
Secondary outcome measures (12)
  • Absolute change in body weight [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Percentage change in body weight [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Achievement in body weight reduction more than or equal to (≥) 5% [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Achievement in body weight reduction ≥ 10% [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Achievement in body weight reduction ≥ 15% [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Achievement in body weight reduction ≥ 20% [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Change in body composition of Lean body mass [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Change in body composition of Total fat mass [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Change in body composition of Lean body mass [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Change in body composition of Total fat mass [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]
  • Change in Body mass index (BMI) [Time frame: From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks]
  • Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2) [Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks]

Eligibility criteria

Inclusion criteria

  • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
  • Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
  • Male or female, aged ≥ 19 years at the time of signing the informed consent.

Exclusion criteria

  • Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
  • Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

South Korea · 1 center
  • Daejeon Endo Internal Medicine Clinic — Daejeon

Identifiers

NCT: NCT07280221 · NN9536-7850 · U1111-1306-1595

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗